beginning dose of tirzepatide Dosage Guide and Chart for Weight Loss Tirzepatide Dosage & Titration: Complete

It could be diabetes because mitochondria shut down their energy burning, and all the energy is being left in the blood, so blood glucose rises

GLP-1 medications are being studied for brain-health and neurodegenerative conditions, but research protocols are not the same thing as informal microdosing claims

Some people are better candidates than others for medically supported weight loss, especially if a GLP-1 prescription is involved

Mechanism of Action Semaglutide: Single GLP-1 Agonist Semaglutide activates only the GLP-1 receptor: GLP-1 Receptor Effects: Stimulates insulin secretion (glucose-dependent) Suppresses glucagon release Slows gastric emptying Reduces appetite via hypothalamic signaling Promotes satiety Tirzepatide: Dual GLP-1/GIP Agonist Tirzepatide activates both GLP-1 and GIP receptors: GLP-1 Receptor Effects: Same as semaglutide (above) GIP Receptor Effects (Additional): Enhanced insulin secretion Direct adipose tissue effects Potential cardioprotective benefits May improve tolerability Complements GLP-1 signaling Why Dual Agonism Matters Semaglutide: GLP-1 Appetite + Glucose Tirzepatide: GLP-1 Appetite + Glucose + GIP Enhanced effects + Better tolerance The dual mechanism may explain tirzepatide's: Greater overall efficacy Potentially better GI tolerability Enhanced metabolic effects Efficacy Comparison Weight Loss Results Semaglutide Clinical Trials STEP 1 (Non-diabetic obesity): 2.4mg dose: 14.9% weight loss Placebo: 2.4% weight loss Duration: 68 weeks STEP 2 (Type 2 diabetes + obesity): 2.4mg dose: 9.6% weight loss Duration: 68 weeks Tirzepatide Clinical Trials SURMOUNT-1 (Non-diabetic obesity): 15mg dose: 20.9% weight loss 10mg dose: 19.5% weight loss Placebo: 3.1% weight loss Duration: 72 weeks SURMOUNT-2 (Type 2 diabetes + obesity): 15mg dose: 15.7% weight loss Duration: 72 weeks Direct Comparison Glycemic Control Side Effects Gastrointestinal Effects GI side effects are the most common with both medications: Key Finding: Tirzepatide shows lower rates of GI side effects despite greater efficacy

& Holmes, C